SOURCE: Cutting Edge Information

July 08, 2008 09:23 ET

New Therapeutic Study by Cutting Edge Information Examines Oncology Market Leaders

RESEARCH TRIANGLE PARK, NC--(Marketwire - July 8, 2008) - New research released last week by pharmaceutical business intelligence firm Cutting Edge Information finds that the oncology market is currently dominated by three companies -- Roche, Amgen and Novartis.

This new report, "Oncology Market Forecast to 2013," examines the oncology portfolios and pipelines at the top fourteen companies in oncology. It analyzes the current market value of each company's oncology products, as well as the company's forecasted positioning in 2013. To view a brochure, please visit

CEI analysts forecast that the oncology market will grow from $57 billion in 2007 to more than $90 billion in 2013. To combat the nightmare of patent expirations on their top-selling drugs, large pharma companies are investing in oncology development. While Roche will continue to hold around 28% of the oncology market, other top companies will slowly reap the rewards of current development. By 2013, nine drug companies are expected to hit sales of more than $4 billion from their oncology portfolios.

According to Eric Bolesh, research team leader at Cutting Edge Information, "Companies across the industry are investing hundreds of millions of dollars in oncology R&D and licensing. This area will be increasingly dominant in the next five to ten years."

The 420+ page report examines more than 130 drugs and provides market analysis on multiple levels, including:

Individual Drug Profiles -- Drug profiles include information about drugs' competitive, strategic and market growth positions based on the following information:

--  Past financial performance and future prospects
--  Patent/litigation information
--  Development progress across all indications
--  Market-changing events, including competitor patent expirations and trial
Oncology Indication Market Outlook -- Detailed outlooks for the breast, colorectal, lung, prostate cancer and leukemia markets. These outlooks are based on the following included information:
--  Epidemiology
--  Drug sales & forecasts
--  Pipeline summaries
--  Market events
--  Marketed products

Company Profiles -- Oncology breakdowns for 14 pharmaceutical and biotechnology companies. These firms have established oncology franchises or exciting development pipelines for new cancer compounds. Research includes:

--  Market share and oncology revenue
--  Competitive and strategic positioning in the oncology market
--  Company performance -- strengths, weaknesses and competitive threats
--  Drug-by-drug examination of company's oncology pipeline

Contact Information